MedTrace Logo

SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues

NCT06832150 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-02-18

No results posted yet for this study

Summary

Recently technology has been developed at the Wellcome Sanger Institute to allow clusters of cells with mutations to be detected in normal and diseased tissues. The researchers wish to determine how the number and nature of these mutant cell clusters change in response to treatments given to cancer patients (such as chemotherapy, radiotherapy, immunotherapy, and drugs targeted at specific mutations in tumours). As such the researchers wish to collect research samples of blood, cheek cells (via swabs) and urine from adult cancer patients receiving the above-mentioned treatments as part of their standard care. The researchers also wish to access any leftover tissue following surgery that is undertaken as part of these patient's treatment.

Conditions

Interventions

OTHER

sample collection

Participants may collected their own cheek swabs and will collect their own urine samples. Clinical professionals at participating sites will collect blood samples.

OTHER

Discussing study

Research Nurse/ Suitably qualified Research Site Staff will discuss the study with potential participants

OTHER

Seeking consent

Potential participants who wish to give consent will do with a Research Nurse/ Suitably qualified Research Site Staff.

Sponsors & Collaborators

  • The Wellcome Sanger Institute

    lead OTHER

Principal Investigators

  • Phil Jones · Wellcome Sanger Institute

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-26
Primary Completion
2028-05-14
Completion
2029-05-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06832150 on ClinicalTrials.gov